RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12,299,574), which broadly covers methods of restoring visual responses with a variety of optogenetic compounds.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups
RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research division of the FDA that took place on May 22 regarding RetroSense’s lead product candidate, RST-001 for vision restoration in retinal degenerative conditions.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups.
RetroSense Therapeutics LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University’s School of Medicine.
In the first clinical trial of gene therapy for treatment of intractable pain, researchers from the University of Michigan Department of Neurology observed that the treatment appears to provide substantial pain relief.
A first-of-its-kind study of gene therapy in the treatment of Parkinson’s disease determined that half of all patients who received the treatment had “clinically meaningful improvements” of their symptoms within six months of surgery
Kalamazoo-based ProNAi Therapeutics Inc., a privately held biopharmaceutical company, announced today dosing of its first patient in an open-label, single-arm, Phase I dose-escalation study of PNT2258 in patients with advanced solid tumors for which no […]